SHL Telemedicine Ltd. (SHLTN.SW) reports earnings tomorrow, April 22, 2026. The Swiss telemedicine company trades at CHF1.09 with a market cap of just $17.87 million. Investors face a challenging picture: the stock has lost 46.8% over the past year and trades near 52-week lows. The company reported negative earnings per share of -0.75 in trailing twelve months. No analyst consensus estimates are available for this earnings report. SHL Telemedicine develops personal ECG devices and remote monitoring solutions for cardiac patients. The company partners with Mayo Clinic and Hebrew University on research initiatives. Tomorrow’s earnings will reveal whether the company can stabilize operations and return to profitability.
Financial Performance and Profitability Challenges
SHL Telemedicine faces significant profitability headwinds heading into this earnings report. The company reported negative net income of -0.63 per share on trailing twelve-month basis, with a net profit margin of -26.2%. Operating income turned negative at -9.3% of revenue, indicating core business operations are unprofitable.
Revenue Trends and Stability
Revenue per share stands at CHF2.42 on a trailing basis. Year-over-year revenue growth was essentially flat at -0.5%, suggesting the company struggles to expand its customer base. However, gross profit margins remain healthy at 47%, indicating the core products generate reasonable margins before operating expenses consume profits.
Operating Expense Burden
Selling, general and administrative expenses consume 46.7% of revenue, leaving minimal room for profitability. Research and development spending accounts for 8% of revenue. Combined, these operating costs exceed gross profit, creating the negative operating income. The company must demonstrate cost discipline or revenue acceleration to return to profitability.
Cash Flow and Balance Sheet Concerns
SHL Telemedicine’s cash position and cash flow metrics reveal ongoing operational stress. Operating cash flow per share turned negative at -0.067, while free cash flow declined to -0.127 per share. The company burns cash from operations, raising questions about sustainability.
Liquidity Position
Cash per share stands at CHF1.04, providing a modest cushion. The current ratio of 1.25 indicates adequate short-term liquidity to cover obligations. However, negative operating cash flow means the company consumes its cash reserves to fund operations. At current burn rates, cash runway becomes a critical concern for investors monitoring this earnings report.
Debt and Capital Structure
Debt-to-equity ratio remains moderate at 0.30, and debt-to-assets at 0.15. The company carries CHF0.59 of debt per share. Interest coverage turns negative due to operating losses, meaning the company cannot cover interest from operating income. This structural weakness limits financial flexibility.
Stock Valuation and Technical Positioning
The stock trades at depressed valuations reflecting market skepticism about the business model. Price-to-sales ratio of 0.39 appears cheap, but this masks underlying profitability problems. The negative price-to-earnings ratio of -2.21 indicates the market prices in ongoing losses.
Valuation Metrics
Price-to-book ratio of 0.78 suggests the stock trades below tangible book value. However, book value per share of CHF1.79 exceeds the current stock price of CHF1.09, indicating potential downside risk if losses continue eroding equity. The enterprise value-to-sales multiple of 0.18 reflects the company’s small scale and limited investor interest.
Technical Signals
The stock shows mixed technical signals ahead of earnings. RSI at 54.9 sits near neutral territory. However, the ADX reading of 67.88 indicates a strong downtrend in place. Stochastic indicators at 100 suggest overbought conditions on short-term charts. Volume remains thin at 17,597 shares daily, typical for micro-cap stocks.
What Investors Should Watch Tomorrow
Tomorrow’s earnings report will focus on whether SHL Telemedicine can stabilize its business and demonstrate a path to profitability. With no analyst estimates available, the company’s own guidance becomes critical for market reaction.
Key Metrics to Monitor
Investors should watch for revenue trends, particularly whether the company achieved any growth in 2026. Operating expense management is crucial—any progress reducing the SG&A burden would signal operational discipline. Management commentary on the Mayo Clinic partnership and AI research collaboration with Hebrew University could indicate future revenue opportunities.
Meyka AI Grade Context
Meyka AI rates SHLTN.SW with a grade of C+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects the company’s weak profitability, negative cash flow, and challenging market position. These grades are not guaranteed and we are not financial advisors. The C+ rating suggests holding rather than buying at current levels.
Final Thoughts
SHL Telemedicine enters tomorrow’s earnings report facing significant operational and financial challenges. The company burns cash, operates unprofitably, and has lost nearly half its value in one year. With no analyst estimates available, the market will focus on management’s ability to articulate a credible path to profitability and growth. The stock’s depressed valuation offers little margin of safety given the fundamental weakness. Investors should demand clear evidence of operational improvement and cost discipline before considering this micro-cap telemedicine play. The C+ Meyka grade reflects these concerns, suggesting caution rather than conviction.
FAQs
What is SHL Telemedicine’s current financial condition?
SHL Telemedicine reports negative earnings of -0.75 per share with a -26% net profit margin. The company burns cash from operations and faces significant profitability challenges. Revenue growth is flat, while operating expenses consume most gross profit.
Why are there no analyst estimates for this earnings?
SHL Telemedicine is a micro-cap stock with only $17.87 million market cap. Limited analyst coverage is typical for small-cap healthcare companies. The lack of estimates means the market will react directly to actual results versus management guidance.
What should investors watch in tomorrow’s earnings?
Monitor revenue trends, operating expense management, and management commentary on partnerships with Mayo Clinic and Hebrew University. Watch for any guidance on achieving profitability. Cash burn rate and liquidity runway are critical metrics for this cash-negative company.
What does the C+ Meyka grade mean for this stock?
The C+ grade reflects weak profitability, negative cash flow, and challenging market position. It suggests holding rather than buying. The grade factors in sector performance, financial metrics, and analyst consensus. These grades are not guaranteed investment advice.
Is the stock cheap at CHF1.09?
While price-to-sales appears cheap at 0.39, the stock trades below book value at 0.78. Valuation is misleading when the company loses money. The depressed price reflects market skepticism about the business model and profitability prospects.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)